Azadirachtin product and process of preparing the same
The humidified drying process effectively addresses high residual solvent and degradation issues in azadirachtin production, achieving regulatory compliance and improved product quality for pharmaceutical and feed applications.
Patent Information
- Application Number
- PCT/US2026/027127
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing azadirachtin production processes face challenges with high residual solvent levels and degradation due to long drying times and high temperatures, which are not in line with regulatory standards.
A humidified drying process is employed, involving humidification at a relative humidity of at least 60% and a temperature below 100°C, followed by drying at 50 to 95°C, to reduce residual solvent content and minimize degradation.
The process significantly reduces residual solvent levels, meeting regulatory guidelines while maintaining azadirachtin integrity, with potential applications in pharmaceuticals and medicated feeds.
Smart Images

Figure IMGF000005_0001 
Figure IMGF000010_0001_TABLE 
Figure IMGF000014_0001_TABLE
Abstract
Description
PT-2365-WO-PCTAZADIRACHTIN PRODUCT AND PROCESS OF PREPARING THE SAMECROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 801,469, filed May 7, 2025, which is incorporated by reference herein in its entirety.FIELD OF INVENTION
[0002] This invention relates to azadirachtin products and methods of making such products.BACKGROUND
[0003] Azadirachtins are a class of natural pesticides that can be isolated from neem tree (Azadirachta indicd) seed processing. Key processing steps to increase chemical purity include purification with several organic solvents such as ethyl acetate and hexanes; however, subsequent long drying times and high temperatures are needed to make a product with low moisture and residual solvents. These drying conditions are conducive to degrading azadirachtins; meanwhile, residual solvent levels can still be problematic and above the acceptable Regulatory thresholds. Therefore, an improved process for preparing an azadirachtin product is needed.SUMMARY
[0004] The present disclosure provides an azadirachtin product low in residual solvents. The azadirachtin product is suitable for use in pharmaceutical or medicated feed applications. For example, the azadirachtin product may comprise 10 to 35 wt% Azadirachtin A, 0 to 100 ppm hexanes, 0 to 3000 ppm ethyl acetate, and 0 to 2 ppm benzene. The azadirachtin product may contain less than 50 ppm hexane, less than 2500 ppm ethyl acetate and 0 ppm benzene. The azadirachtin product is preferably obtained by a humidified drying process. The azadirachtin product contains a significant amount of azadirachtin A, and may contain significant amounts of other azadirachtins, including azadirachtin B and azadirachtin D.
[0005] The present disclosure provides a process for preparing an azadirachtin product comprising the steps of providing an azadirachtin containing material; humidifying the azadirachtin containing material at a relative humidity of at least 60% and a humidifying temperature of less than 100°C to obtain a humidified material; and drying the humidified material to obtain the azadirachtin product. The resulting azadirachtin product has a reduced residual solvent content as compared to an equivalent untreated azadirachtin product.PT-2365-WO-PCT
[0006] The present disclosure also provides a process for reducing residual solvent content of an azadirachtin product comprising the steps of humidifying an azadirachtin containing material at a relative humidity of at least 60% and a humidifying temperature of less than 100°C to obtain a humidified material; and drying the humidified material at a drying temperature from 50 to 95°C to obtain the azadirachtin product. The resulting azadirachtin product has a reduced residual solvent content as compared to an equivalent untreated azadirachtin product.
[0007] The present disclosure also provides an azadirachtin product having content of one or more residual solvents reduced as compared to an equivalent untreated azadirachtin product.BRIEF DESCRIPTION OF THE FIGURES
[0008] The drawings illustrate generally, by way of example, but not by way of limitation, various aspects discussed in the present document.
[0009] Figure 1 shows peaks detected in a chromatography study of neem extract (Fortune) samples with different treatment conditions: untreated samples (top panel), samples dried without humidification (middle panel), and samples dried with humidification (bottom panel).
[0010] Figure 2 shows peaks detected in a chromatography study of neem extract (Coromandel) samples with different treatment conditions: untreated samples (top panel), samples dried without humidification (middle panel), and samples dried with humidification (bottom panel).DETAILED DESCRIPTION
[0011] Reference will now be made in detail to certain aspects of the disclosed subject matter. While the disclosed subject matter will be described in conjunction with the enumerated claims, it will be understood that the exemplified subject matter is not intended to limit the claims to the disclosed subject matter.
[0012] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one skilled in the art to which this invention belongs. As used herein, each of the following terms has the meaning associated with it as defined below.
[0013] Unless expressly stated, ppm (parts per million), percentage, and ratios are based on a dry weight basis. Percentage based on a dry weight basis is also referred to as wt% below.
[0014] The term "for example," "for instance," "such as," or "including" as used herein is meant to introduce examples that further clarify more general subject matter. Unless otherwise specified, these examples are provided only as an aid for understanding the applications illustrated in the present disclosure and are not meant to be limiting in any fashion.PT-2365-WO-PCT
[0015] As used herein, “room temperature” or “RT” refers to a temperature between 20°C to 25°C.
[0016] In the processes described herein, the acts can be carried out in any order without departing from the principles of the disclosure, except when a temporal or operational sequence is explicitly recited. Furthermore, specified acts can be carried out concurrently unless explicit claim language recites that they be carried out separately. For example, a claimed act of doing X and a claimed act of doing Y can be conducted simultaneously within a single operation, and the resulting process will fall within the literal scope of the claimed process.
[0017] Described herein is an azadirachtin product and a process of preparing the azadirachtin product. The azadirachtin product thus prepared has a reduced residual solvent content and is suitable for use in different applications (e.g., pest control).Process for preparing an azadirachtin product
[0018] The present disclosure provides a process for preparing an azadirachtin product. The process starts with humidifying an azadirachtin containing material at a relative humidity of at least 60% and a humidifying temperature of less than 100°C. The obtained humidified material is dried to obtain the azadirachtin product. The resulting azadirachtin product has one or more improved attributes compared to an equivalent untreated azadirachtin product; preferably, the one or more improved attributes may include, but may not be limited to, a reduced residual solvent content.
[0019] As described herein, an “equivalent untreated azadirachtin product” refers to an equivalent azadirachtin product that has not been subjected to any process of the instant invention as described in the present disclosure. An example of an equivalent untreated azadirachtin product can be an equivalent azadirachtin product dried using conventional methods at a low relative humidify less than 60% (e.g., between around 40% and around 60%). An “equivalent azadirachtin product” refers to an azadirachtin product prepared from the same starting material used in the instant invention (e.g., neem extract from the same batch).
[0020] The azadirachtin containing material serves as a starting material to the process. As used herein, the terms “azadirachtin” or “azadirachtins” refers to a collective term applied to a large group of active compounds and is intended to encompass not only all naturally occurring variants or derivatives of azadirachtin, including but not limited to, azadirachtin A, azadirachtin B, azadirachtin D, azadirachtin E, azadirachtin F, azadirachtin G, azadirachtin H, azadirachtin I, azadirachtin K, but also all synthetic variants, fragments, analogues, and derivatives thereof. InPT-2365-WO-PCTthis regard, it will be appreciated that any azadirachtin variants, fragments, analogues, or derivatives for use herein should be functional, in that they exhibit at least one inhibitory effect as described.
[0021] The azadirachtin containing material can be obtained from a plant belonging to the genus Azadirachta. The azadirachtin containing material can be obtained or extracted from Azadirachta indica - a tree commonly known as the “Neem” tree. Extracts prepared from plants belonging to the genus Azadirachta (e.g., Azadirachta indica) can include potent terpenoid compounds, including one or more azadirachtinoids. The azadirachtinoids include azadirachtin compounds such as azadirachtin A. azadirachtin B. azadirachtin D. azadirachtin E. azadirachtin F, azadirachtin G, azadirachtin H, azadirachtin I, azadirachtin K, and / or other azadirachtin variants. The extracts from plants belonging to the genus Azadirachta can also include many other components in various quantities. In some aspects, the extracts can include additional compounds such as the limonoids salannin, nimbin, deacetyl salinin, and 6-desacetylnimbin. In various aspects, the extracts can further include one or more azadirachtinins.
[0022] Azadirachtin can be obtained or extracted from any part of the Azadirachta indica plant including, for example, leaves, stems, bark, fruit, seeds, or any combinations thereof by one or more extraction processes. In one aspect, the azadirachtin suitable for use herein includes azadirachtin A, which is by its scientific name of dimethyl [2a / ?- [2aa,3B,4B(la / ?*,2S*,3aS’*,6a ’*,7S*,7aS'*),4aB,5a,7aS*,8B(E),10B,10aa,10bB]]-10-(acetyloxy)octahydro-3,5-dihydroxy-4-methyl-8-[(2-methyl-l-oxo-2-butenyl)oxy]-4-(3a,6a,7,7a)-tetrahydro-6a-hydroxy-7a-methyl-2,7-methanofuro[2,3-Z>]oxireno[e]oxepin-la(277)-yl)-l / / .7 / / -naphtho-| l.8- / ic:4.4rz-c ‘]difuran-5,10a(8 / 7)-dicarboxylate.
[0023] Azadirachtin A is the most abundant group of the azadirachtinoids, which are potent terpenoid compounds present in extracts prepared from plants belonging to the genus Azadirachta (e.g., Azadirachta indica). For example, Azadirachtin A makes up about 80% of the azadirachtinoids in the neem seed kernel. The structural formula of azadirachtin A is:PT-2365-WO-PCT
[0024] In one aspect, the azadirachtin containing material may have an azadirachtin content in a range from 5 to 100 wt%. Preferably, the azadirachtin containing material may include azadirachtin A in which the azadirachtin A content may be at least 10 wt%, for example from 10 to 60 wt%, from 15 to 50 wt%, or from 20 to 40 wt%, based on the total weight of the azadirachtin containing material. In one aspect, the azadirachtin A content of the azadirachtin containing material is (dry basis) in the range of 10 to 35 wt%, 10 to 30 wt%, 20 to 35 wt%, 20 to 30 wt%, 25 to 35 wt%, 25 to 30 wt%. 26 to 29 wt%, or 27 to 30 wt%.
[0025] The azadirachtin containing material may contain significant amounts of other azadirachtins, including but not limited to azadirachtin B (3-tigloyl-azadirachtol or dimethyl (1S,4S,5R,6S,7S,8R,1 lS,12R,14S,15R)-7,14-dihydroxy-6-[(lS,2S,6S,8S,9R,l lS)-2-hydroxy-ll-methyl-5,7,10-trioxatetracyclo[6.3.1.02,6.09,ll]dodec-3-en-9-yl]-6-methyl-12-[(E)-2-methylbut-2-enoyl]oxy-3,9-dioxatetracyclo[6.6.1.01,5.011,15] pentadecane-4,11 -dicarboxylate) and azadirachtin D (methyl (1S,4S,5R,6S,7S,8S,1 lR,12R,14S,15S)-12-acetyloxy-4,7-dihydroxy-6-[(lS,2S,6S,8S,9R,llS)-2-hydroxy-ll-methyl-5,7,10-trioxatetracyclo[6.3.1.02,6.09,ll]dodec-3-en-9-yl] -6,11 -dimethyl- 14- [(E)-2-methy lbut-2-enoyl] oxy-3,9-dioxatetracyclo[6.6.1.01,5.011,15]pentadecane-4-carboxylate). In one aspect, the azadirachtin B content of the azadirachtin containing material is (dry basis) in the range of 1 to 15 wt%, 1 to 10 wt%, 5 to 15 wt%, or 5 to 10 wt%. In one aspect, the azadirachtin D content of the azadirachtin containing material is (dry basis) in the range of 0.1 to 5 wt%, 0.1 to 4 wt%, 0.5 to 4 wt%, 1 to 4 wt%, 2 to 4 wt%, or 3 to 5 wt%.
[0026] In one aspect, the azadirachtin containing material may have a total azadirachtin content (including azadirachtin A, azadirachtin B, azadirachtin D, azadirachtin E, azadirachtin F, azadirachtin G, azadirachtin H, azadirachtin I, azadirachtin K, other azadirachtins, and isomersPT-2365-WO-PCTthereof) in a range from 10 to 100 wt%, 15 to 100 wt%, 20 to 100 wt%, 25 to 100 wt%, 30 to 100 wt%, 35 to 100 wt%, 45 to 100 wt%, 50 to 100 wt%, 60 to 100 wt%, 70 to 100 wt%, 80 to 100 wt%, 85 to 100 wt%, 90 to 100 wt%, 50 to 99 wt%, 60 to 99 wt%, 70 to 99 wt%, 80 to 99 wt%, 85 to 99 wt%, 90 to 99 wt%, 50 to 95 wt%, 60 to 95 wt%, 70 to 95 wt%. 80 to 95 wt%, 85 to 95 wt%. or 90 to 95 wt%.
[0027] In one aspect, the azadirachtin containing material may have a total content of azadirachtin A, azadirachtin B, and azadirachtin D in a range from 10 to 50 wt%, 15 to 50 wt%, 20 to 50 wt%, 25 to 50 wt%, 30 to 50 wt%, 35 to 50 wt%, 25 to 45 wt%, or 25 to 40 wt%.
[0028] The high azadirachtin content of the azadirachtin product of the present disclosure can increase the difficulty in removing solvents typically used in the processing of materials suitable for pharmaceuticals or medicated feed, for example ethyl acetate and hexane.
[0029] In the humidifying step, the azadirachtin containing material can be exposed to an atmosphere comprising, preferably a high relative humidity, more preferably a high relative humidity and a high humidifying temperature, to remove a substantial fraction of compounds. The removed compounds may include, but may not be limited to, organic compounds, volatile compounds, or any combinations thereof.
[0030] In one aspect, the humidifying step at high relative humidity is more effective at elevated humidifying temperatures, but the humidifying temperature is not desirably to exceed 100°C. Preferably, steam is not used in the humidifying step to avoid degradation of the starting material.
[0031] Preferably, the atmosphere contacting the azadirachtin containing material should be exchanged so that the removed compounds can be swept away, but air velocity should be kept low enough to prevent the azadirachtin containing material itself from being swept away. In other words, the air velocity should be maintained low enough to only remove the liberated compounds but not the azadirachtin containing material itself.
[0032] The relative humidify at the humidifying step can be 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100%. In one aspect, the relative humidity can be at least 60%, preferably at least 75%, more preferably at least 90%. Examples of the relative humidity may include, but may not be limited to, a range from 60 to 100%, from 60 to 99%, from 60 to 90%, from 70 to 100%, from 70 to 99%, from 70 to 90%, or from 70 to 80%.
[0033] The humidifying temperature at the humidifying step can be 30°C, 40°C, 50°C, 70°C, 80°C, 90°C, or 95°C. In one aspect, the humidifying temperature can be at least 30°C or at most 95°C. Examples of the humidifying temperature may include, but may not be limited to, a rangePT-2365-WO-PCTfrom 30 to 95°C, from 30 to 90°C, from 50 to 95°C, from 50 to 90°C, from 70 to 95 °C, or from 70 to 90°C.
[0034] In one aspect, the humidifying step is carried out by passing humidified or warmed air to deliver water to the azadirachtin containing material over one or more static beds, or one or more fluid beds. A fluid bed system that can improve air-particle contact and mass transfer may be desired. Preferably, water is uniformly delivered and distributed over the azadirachtin containing material; more preferably, water is delivered in a form of a vapor; even more preferably, water delivered is not in a form of liquid water or not in a form of steam.
[0035] In one aspect, the humidifying step is carried out by adding liquid water to the azadirachtin containing material over one or more static beds. The water can be added to the azadirachtin containing material by spraying or other suitable method.
[0036] The humidifying period for humidifying the azadirachtin containing material is a function of humidifying temperature, relative humidity, surface area of the starting material, particle size of the starting material, or any combinations thereof. In one aspect, the humidifying period can be 2 minutes, 5 minutes, 10 minutes, 30 minutes, 60 minutes, 90 minutes, or 120 minutes. For example, the humidifying period can be in a range from 2 to 120 minutes, from 5 to 90 minutes, from 10 to 60 minutes, or from 20 to 40 minutes. In one aspect, the humidifying period can be at least 120 minutes.
[0037] The humidified material can be de-humidified in the drying step to obtain the final azadirachtin product. The drying step can be carried out at a drying temperature for a drying period to obtain the azadirachtin product. If excess moisture is absorbed by the humidified material, gentle drying can remove the excess moisture and restore and / or establish the desired moisture content in the azadirachtin product.
[0038] The humidified material can be dried under a drying medium that may include, but may not be limited to, nitrogen, air, or any combinations thereof.
[0039] The drying temperature can be less than 100°C and can be 50°C, 55°C, 60°C, 70°C, 75°C, 85°C, 90°C, or 95°C. In one aspect, the drying temperature can be at least 50°C or at most 95°C. Examples of the drying temperature may include, but may not be limited to, a range from 50 to 95°C, from 50 to 85°C, from 60 to 95°C, from 60 to 90°C, from 70 to 95°C, from 70 to 90°C, or from 80 to 95°C.
[0040] The drying period can be 15 minutes, 20 minutes. 25 minutes, 35 minutes, 40 minutes, or 45 minutes. For example, the drying period can be in a range from 15 to 45 minutes, from 20 toPT-2365-WO-PCT40 minutes, from 25 to 35 minutes. In one aspect, the drying period can be at most 15 minutes. In another aspect, the drying period can be at least 45 minutes.
[0041] In one aspect, each of the humidifying step and the drying step can be performed for one or more than one time. Preferably, the humidifying step and the drying step can be carried out as a cycle and the cycle can be performed for one or more than one time. Cycling of humidifying step and drying step may enhance the efficiency and yield of the process.
[0042] The azadirachtin product obtained from the process as described above has content of one or more residual solvents reduced as compared to an equivalent untreated azadirachtin product. Preferably, the content of one or more residual solvents in the azadirachtin product can be reduced by at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%, as compared to an equivalent untreated azadirachtin product.Process for reducing residual solvent content of an azadirachtin product
[0043] The present disclosure provides a process for reducing residual solvent content of an azadirachtin product. As used herein, “residual solvents” are chemicals (e.g., organic volatile chemicals) that are used in the preparation (e g., extraction or isolation from any part of the Azadirachta indica plant) of an azadirachtin containing material (i.e., the starting material of the process described in the present disclosure). These residual solvents are not completely removed by the preparation process and remain with the azadirachtin containing material. Examples of the residual solvents may include, but may not be limited to, hexane, ethyl acetate, cyclohexane, benzene, 2,3-dimethyl-butane, 2-methyl-pentane, 3-methyl-pentane, 2,2-dimethyl-butane, 2,4-dimethyl-butane, methyl-cyclopentane, or any combinations thereof.
[0044] The process comprises a step of humidifying an azadirachtin containing material at a relative humidity of at least 60% and a humidifying temperature of less than 100°C to obtain a humidified material. The humidified material is then dried at a drying temperature from 50 to 95°C to obtain the azadirachtin product. The resulting azadirachtin product has content of one or more residual solvents reduced by' at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%, as compared to an equivalent untreated azadirachtin product.
[0045] During the humidifying step, the azadirachtin containing material can be humidified at a relative humidity at least 60%, preferably at least 75%, more preferably at least 90%, and at a humidifying temperature in a range from 30 to 95°C, from 50 to 95°C, or from 70 to 95°C. ThePT-2365-WO-PCTazadirachtin containing material can be humidified for a humidifying period in a range from 2 to 120 minutes, from 5 to 90 minutes, or from 10 to 60 minutes.
[0046] The humidified material can be dried at a drying temperature in a range from 50 to 95°C, from 70 to 95°C, or from 80 to 95°C, for a drying period in a range from 15 to 45 minutes, from 20 to 40 minutes, or from 25 to 35 minutes to obtain the azadirachtin product.
[0047] In one aspect, each of the humidifying step and the drying step can be performed for one or more than one time. Preferably, the humidifying step and the drying step can be carried out as a cycle and the cycle can be performed for one or more than one time. Cycling of humidifying step and drying step may enhance the efficiency and yield of the process.
[0048] One advantage of the humidification-drying process as described in the present disclosure is that concentrations of residual solvents can be dramatically reduced even for short drying periods and with less harsh drying temperatures. Another important advantage is that azadirachtin degradation can be significantly decreased and the resulting azadirachtin content can thus be improved. Azadirachtin products dried conventionally cannot reach low enough levels without significant degradation to active ingredients of the azadirachtin products, and residual solvent content of the azadirachtin products prepared by the process as described in the present disclosure may be reduced to a low level, preferably below a corresponding regulatory guideline level, without significant degradation to the ingredients (e.g., azadirachtin A) of the azadirachtin product. As less severe drying conditions are used during the process, energy consumption can be decreased.Azadirachtin product
[0049] The azadirachtin product disclosed herein is derived from a process that includes a humidifying step during drying. The azadirachtin product of the instant invention has one or more improved attributes as compared to an equivalent untreated azadirachtin product. The one or more attributes that are improved compared to an equivalent untreated azadirachtin product may include, but may not be limited to. a reduced residual solvent content.
[0050] Preferably, the azadirachtin product described in the present disclosure may have a reduced residual solvent content as compared to an equivalent untreated azadirachtin product. More preferably, the residual solvents may include, but may not be limited to, hexane, ethylacetate, cyclohexane, benzene, 2.3-dimethyl-butane, 2-methyl-pentane, 3-methyl-pentane, 2,2-dimethyl-butane, 2,4-dimethyl-butane, methyl-cyclopentane, or any combinations thereof.PT-2365-WO-PCT
[0051] Preferably, the azadirachtin product described in the present disclosure may have content of one or more residual solvents reduced by at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%, as compared to an equivalent untreated azadirachtin product.
[0052] In one aspect, the content of one or more residual solvents in the azadirachtin product is reduced, preferably below a Regulatory guideline level, as compared to an equivalent untreated azadirachtin product. A Regulatory guideline level refers to an acceptable amount, recommend by an institution (e.g., an international organization, a government agency), for an ingredient present in a product for the safety of use and / or consumption. For example, the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (I CH) releases a Q3C(R9) guideline (Impurities: Guideline for Residual Solvents) that recommends acceptable amounts of residual solvents in pharmaceuticals for the safety of the patient. Table 1 below shows concentration limits of some of the residual solvents.Table 1.
[0053] The azadirachtin product described in the present disclosure may have an ethyl acetate content below a regulatory guideline level for ethyl acetate. For example, the ethyl acetate content of the azadirachtin product may be below 0.5%. In one aspect, the azadirachtin product may have an ethyl acetate content reduced by at least 35%, preferably at least 55%, more preferably at least 75%, or even more preferably up to 100%, as compared to an equivalent untreated azadirachtin product. In one aspect, the ethyl acetate content of the azadirachtin product in ppm is less than 5000, less than 4000. less than 3000, less than 2500, less than 2000, less than 1500, less than 1400, less than 1300, less than 1200, less than 1100, less than 1000, less than 500, less than 100, or none detected. In one aspect, the ethyl acetate content of the azadirachtin product in ppm is in the range of 0 to 5000, 0 to 4000, 0 to 3500, 0 to 3000, 0 to 2500, 0 to 2000, 0 to 1500, 0 to 1400, 0 to 1300, 0 to 1200, 0 to 1100, 0 to 1000, 0 to 500, 0.1 to 5000, 0.1 to 4000, 0.1 to 3500, 0.1 to 3000, 0.1 toPT-2365-WO-PCT2500, 0.1 to 2000, 0.1 to 1500, 0.1 to 1400, 0.1 to 1300, 0.1 to 1200, 0.1 to 1100, 0.1 to 1000, 0.1 to 500, 500 to 5000, 500 to 4000, 500 to 3500, 500 to 3000, 500 to 2500, 500 to 2000, 500 to 1500, or 500 to 1000.
[0054] Preferably, the azadirachtin product described in the present disclosure may have a hexane content below a regulatory guideline level for hexane. For example, the hexane content of the azadirachtin product may be below 290 ppm. In one aspect, the azadirachtin product may have a hexane content reduced by at least 50%, preferably at least 75%, preferably at least 90%, more preferably at least 99%, or even more preferably up to 100%, as compared to an equivalent untreated azadirachtin product. In one aspect, the n-hexane content of the azadirachtin product in ppm is less than 250, less than 200, less than 150, less than 100, less than 50, less than 40, less than 35, less than 34, less than 33, less than 32, less than 31, less than 30, less than 29, less than 28, less than 27, less than 26, less than 25, less than 24, less than 23, less than 22, less than 21, less than 20, less than 19, less than 18, less than 17, less than 16, less than 15, less than 14. less than 13, less than 12, less than 11, less than 10, less than 5, or none detected. In one aspect, the hexane content of the azadirachtin product in ppm is in the range of 0 to 250, 0 to 200, 0 to 150, 0 to 100, 0 to 50, 0 to 40, 0 to 35, 0 to 20, 0 to 15, 0 to 10, 0.1 to 250, 0.1 to 200, 0.1 to 150, 0.1 to 100, 0.1 to 50, 0.1 to 40, 0.1 to 35, 0.1 to 20, 0.1 to 15, 0.1 to 10, 5 to 100, 5 to 50, 5 to 40, 5 to 35, 5 to 20. 5 to 15, 5 to 10, 1 to 100, 1 to 50, 1 to 40. 1 to 35, 1 to 20, 1 to 15, 1 to 10. 1 to 5, 10 to 100, 10 to 50, 10 to 40, 10 to 35, 10 to 30, 10 to 20, or 10 to 15. Preferably, the azadirachtin product described in the present disclosure may have a cyclohexane content below a regulatory guideline level for cyclohexane. For example, the cyclohexane content of the azadirachtin product may be below 3,880 ppm. Preferably, the azadirachtin product may have a cyclohexane content reduced by at least 50%, preferably at least 75%, preferably at least 85%, more preferably at least 95%, or even more preferably up to 100%, as compared to an equivalent untreated azadirachtin product.
[0055] Preferably, the azadirachtin product described in the present disclosure may have a benzene content below a regulatory guideline level for benzene. For example, the benzene content of the azadirachtin product may be below 2 ppm. Preferably, the azadirachtin product may have a benzene content reduced by at least 50%, preferably at least 75%, preferably at least 85%, more preferably at least 95%, or even more preferably up to 100%, as compared to an equivalent untreated azadirachtin product. The benzene content of the azadirachtin product can be less than 2 ppm, less than 1 ppm, less than 0.5 ppm, or none detected. In one aspect, the benzene content of the azadirachtin product is in the range of 0 to 2 ppm, 0 to 1.5 ppm, 0 to 1 ppm, or 0 to 0.5 ppm.PT-2365-WO-PCT
[0056] The method used for residual solvent analysis is a GC-MS headspace method as defined in 2.4.24. Identification and control of residual solvents, EUROPEAN PHARMACOPOEIA 11.0, pp. 162 to 166, which is hereby incorporated by reference in its entirety.
[0057] The azadirachtin product described in the present disclosure may have a loss on drying content below a regulatory guideline level for water and total solvents. Loss on drying is the loss of mass after drying under specified conditions, calculated as a percentage (m / m). For example, the loss on dry ing (LOD) content of the azadirachtin product may be less than 5%. The loss on drying (LOD) content of the azadirachtin product may be less than 4%, less than 3%, less than 2%, or less than 1%. The loss on drying (LOD) content of the azadirachtin product may be in the range of 0.1 to 5%, 0.1 to 4% 0.1 to 3% 0.1 to 2.5%, 0.1 to 2% 0.1 to 1.5%. 0.1 to 1%, or 0.1 to 0.5%. The method used for loss on drying analysis is as defined in 2.2.32. Loss on Drying, EUROPEAN PHARMACOPOEIA 11.0, p. 63, which is hereby incorporated by reference in its entirety.
[0058] The azadirachtin product of the present disclosure may have an impurity content below a regulatory guideline level for azadirachtin degradants or other impurities associated with producing a product derived from a neem extract. The azadirachtin product may have a nimbin (C30H36O9) content of less than 0.5 wt%, less than 0.4 wt%, less than 0.3 wt%, less than 0.2 wt%. or less than 0.1 wt%. The azadirachtin product may have a salanin (C34H44O9) content of less than 1.6 wt%, less than 1.5 wt%, less than 1.4 wt%, less than 1.3 wt%, less than 1.2 wt%, less than 1.1 wt%, less than 1.0 wt%, less than 0.9 wt%, less than 0.8 wt%, less than 0.7 wt%, less than 0.6 wt%, less than 0.5 wt%, less than 0.4 wt%, less than 0.3 wt%, less than 0.2 wt%, or less than 0.1 wt%. The azadirachtin product may have a deacetylnimbin (6-Deacetylnimbincontent; C28H34O8) of less than less than 1.0 wt%, less than 0.9 wt%, less than 0.8 wt%, less than 0.7 wt%, less than 0.6 wt%, less than 0.5 wt%, less than 0.4 wt%, less than 0.3 wt%, less than 0.2 wt%, or less than 0.1 wt%. The azadirachtin product may have a deacetylnimbin (3-Deacetylsalannin; C32H42O8) of less than less than 1.0 wt%, less than 0.9 wt%, less than 0.8 wt%. less than 0.7 wt%. less than 0.6 wt%, less than 0.5 wt%, less than 0.4 wt%, less than 0.3 wt%, less than 0.2 wt%, or less than 0.1 wt%.
[0059] In the present disclosure, the method used for determining the content of azadirachtins, liminoids, and / or impurities in the azadirachtin product is a suitable UHPLC / UV method. All percent values of azadirachtins, liminoids, and / or impurities are expressed in weight % dry basis unless noted otherwise or as would be understood differently by a person of skilled in the art.PT-2365-WO-PCT
[0060] In one aspect, atributes other than a reduced residual solvent content of the azadirachtin product prepared by any process of the instant invention described in the present disclosure can be improved as compared to an equivalent untreated azadirachtin product. For example, the azadirachtin product prepared by any process of the instant invention described in the present disclosure can have an improved azadirachtin content and / or a reduced azadirachtin degradation.
[0061] The azadirachtin product of the present disclosure can be incorporated into an animal feed additive, a complete feed, or a feed diet. The animal feed additive, complete feed, or feed diet can include an amount of azadirachtin product effective for use against pests or parasites in animals, including livestock, pets, lifestyle, and aquaculture animals. The animal feed additive, complete feed, or feed diet can include an amount of azadirachtin product effective for use against sea lice in salmonids or other fish. Accordingly, the azadirachtin product of the present disclosure can be incorporated into a fish feed or an additive for fish feed. The azadirachtin product of the present disclosure may be suitable for pharmaceutical applications or as a medicated feed.
[0062] Further discussion about the use of azadirachtin for reducing, preventing, or controlling a parasitic infection or infestation in fish can be found in patent application nos. PCT / US2023 / 077893, filed 26 October 2023, or PCT / GB2014 / 050803, filed 14 March 2014, both of which are hereby incorporated by reference in their entirety'.EXAMPLES
[0063] The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.Example 11.1. Materials and Method
[0064] Samples from neem extracts from two manufacturers (Fortune; Coromandel) were studied. For each neem extract, approximately 1 g were dried under two treatment conditions. The dried-without-humidification samples were heated at 80°C for 30 minutes in an enclosed environment using sodium chloride solution to provide a humidity of 75% relative humidity (RH). The dried-with-humidification samples were heated at 80°C for 30 minutes in absence of the above humidity condition.PT-2365-WO-PCT
[0065] The untreated samples and both treated (dried-without-humidification and dried-with-humidification) samples were analyzed using a gas chromatography (GC) flame ionization detector (FID) method. Samples were diluted in methanol containing an internal standard. Volatile compounds were separated via hydrogen carrier gas on a Restek RXI-624MS 60m column.1.2 Results and Discussion
[0066] Ten volatile compounds were detected and identified in both the Fortune and Coromandel neem extract samples (Figures 1 and 2). As observed from Tables 2 to 4, which show the removal percentages of the identified volatile compounds in the treated Fortune and Coromandel neem extract samples, some of the identified volatile compounds were significantly removed by the treatment of dry ing with humidification (i.e., the treatment process described in the present disclosure).Table 2.Table 3.PT-2365-WO-PCTTable 4.1.3 Conclusion
[0067] Modification of the drying process of neem extracts to include high humidity dramatically reduced the concentration of volatile compounds, even during short drying times, such as 30 minutes. Drying with humidification was shown to drastically reduce concentrations of some of the volatile compounds.Additional Examples
[0068] The following examples are further examples of the invention disclosed herein.
[0069] Example A-l. A process for preparing an azadirachtin product, comprising the steps of: providing an azadirachtin containing material; humidifying the azadirachtin containing material at a relative humidity of at least 60% and a humidifying temperature of less than 100°C to obtain a humidified material: and drying the humidified material to obtain the azadirachtin product; wherein the azadirachtin product has a reduced residual solvent content as compared to an equivalent untreated azadirachtin product.
[0070] Example A-2. The process of Example A-l, wherein the relative humidity' is at least 60%, preferably at least 75%, more preferably at least 90%.
[0071] Example A-3. The process of any of the preceding examples, wherein the humidifying temperature is in a range from 30 to 95°C.
[0072] Example A-4. The process of any of the preceding examples, wherein the azadirachtin containing material is humidified for a humidifying period in a range from 2 to 120 minutes.
[0073] Example A-5. The process of any of the preceding examples, wherein the humidified material is dried for a drying temperature in a range from 50 to 95°C, preferably from 70 to 95°C, more preferably from 80 to 95°C.
[0074] Example A-6. The process of any of the preceding examples, wherein the humidified material is dried for a drying period in a range from 15 to 45 minutes, preferably from 20 to 40 minutes, more preferably from 25 to 35 minutes.PT-2365-WO-PCT
[0075] Example A-7. A process for reducing residual solvent content of an azadirachtin product, comprising the steps of: humidifying an azadirachtin containing material at a relative humidity of at least 60% and a humidifying temperature of less than 100°C to obtain a humidified material; and drying the humidified material at a dry ing temperature from 50 to 95°C to obtain the azadirachtin product; wherein the azadirachtin product has a reduced residual solvent content as compared to an equivalent untreated azadirachtin product.
[0076] Example A-8. The process of example 7, wherein the humidifying step is performed at a humidifying temperature in a range from 30 to 100°C.
[0077] Example A-9. The process of any of examples A-7 to A-8, wherein the azadirachtin product has content of one or more residual solvents reduced by at least 40% as compared to an equivalent untreated azadirachtin product.
[0078] Example A- 10. The process of any of examples A-7 to A-9, wherein the one or more residual solvents are selected from the group consisting of hexane, ethyl-acetate. cyclohexane, benzene, 2,3-dimethyl-butane, 2-methyl-pentane, 3-methyl-pentane, 2,2-dimethyl-butane, 2,4-dimethyl-butane, methyl-cyclopentane, and any combinations thereof.
[0079] Example A-ll. An azadirachtin product prepared by the process of any of the preceding examples.
[0080] Example A- 12. An azadirachtin product having content of one or more residual solvents reduced as compared to an equivalent untreated azadirachtin product.
[0081] Example A-13. The azadirachtin product of any of examples A-ll to A-12, having content of one or more residual solvents reduced by at least 40% as compared to an equivalent untreated azadirachtin product.
[0082] Example A-14. The azadirachtin product of any of examples A-ll to A-13, wherein the one or more residual solvents are selected from the group consisting of hexane, ethyl-acetate, cyclohexane, benzene, 2,3-dimethyl-butane, 2-methyl-pentane, 3-methyl-pentane, 2,2-dimethyl-butane, 2,4-dimethyl-butane, methyl-cyclopentane, and any combinations thereof.
[0083] Example B-l. An azadirachtin product, comprising: 10 to 35 wt% azadirachtin A. 0.1 to 100 ppm hexane, 0.1 to 3000 ppm ethyl acetate, and 0 to 2 ppm benzene.
[0084] Example B-2. The azadirachtin product of example B-l, wherein the azadirachtin product comprises azadirachtin B in an amount from 1 to 15 wt%.
[0085] Example B-3. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises azadirachtin D in an amount from 0.1 to 5 wt%.PT-2365-WO-PCT
[0086] Example B-4. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises a total content of azadirachtin A, azadirachtin B, and azadirachtin D of from 25 to 45 wt%.
[0087] Example B-5. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises azadirachtin A in an amount from 25 to 30 wt%.
[0088] Example B-6. The azadirachtin product of any of the preceding examples, wherein the loss on dry ing of the azadirachtin product is less than 3%.
[0089] Example B-7. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises 0.1 to 50 ppm hexane.
[0090] Example B-8. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises 0.1 to 2500 ppm ethyl acetate.
[0091] Example B-9. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises no detectable benzene.
[0092] Example B-10. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises less than 0.5% nimbin.
[0093] Example B-ll. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises less than 1.6% salanin.
[0094] Example B-12. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises a total azadirachtin content (including azadirachtin A, azadirachtin B, azadirachtin D, azadirachtin E, azadirachtin F, azadirachtin G, azadirachtin H, azadirachtin I, azadirachtin K, other azadirachtins, and isomers thereof) of from 50 to 100%.
[0095] Example B-13. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises azadirachtin A in the range of 10 to 35 wt%, 10 to 30 wt%, 20 to 35 wt%, 20 to 30 wt%, 25 to 35 wt%, 25 to 30 wt%, 26 to 29 wt%, or 27 to 30 wt%.
[0096] Example B-14. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises azadirachtin B in the range of 1 to 15 wt%, 1 to 10 wt%, 5 to 15 wt%, or 5 to 10 wt%.
[0097] Example B-15. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises azadirachtin D in the range of 0.1 to 5 wt%, 0.1 to 4 wt%, 0.5 to 4 wt%, 1 to 4 wt%, 2 to 4 wt%, or 3 to 5 wt%.
[0098] Example B-16. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises a total azadirachtin content (including azadirachtin A, azadirachtin B, azadirachtin D, azadirachtin E, azadirachtin F, azadirachtin G, azadirachtin H, azadirachtin I,PT-2365-WO-PCTazadirachtin K, other azadirachtins, and isomers thereof) in a range from 10 to 100 wt%, 15 to 100 wt%, 20 to 100 wt%, 25 to 100 wt%, 30 to 100 wt%, 35 to 100 wt%, 45 to 100 wt%, 50 to 100 wt%, 60 to 100 wt%, 70 to 100 wt%, 80 to 100 wt%, 85 to 100 wt%, 90 to 100 wt%, 50 to 99 wt%, 60 to 99 wt%, 70 to 99 wt%, 80 to 99 wt%, 85 to 99 wt%, 90 to 99 wt%, 50 to 95 wt%, 60 to 95 wt%. 70 to 95 wt%, 80 to 95 wt%. 85 to 95 wt%, or 90 to 95 wt%.
[0099] Example B-21. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises a total content of azadirachtin A, azadirachtin B, and azadirachtin D in a range from 10 to 50 wt%, 15 to 50 wt%, 20 to 50 wt%, 25 to 50 wt%, 30 to 50 wt%, 35 to 50 wt%, 25 to 45 wt%. or 25 to 40 wt%.
[0100] Example B-17. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises an ethyl acetate content in ppm in the range of 0 to 5000, 0 to 4000, 0 to 3500, 0 to 3000, 0 to 2500, 0 to 2000, 0 to 1500, 0 to 1400, 0 to 1300, 0 to 1200, 0 to 1100, 0 to 1000, 0 to 500, 0.1 to 5000, 0.1 to 4000. 0.1 to 3500, 0.1 to 3000, 0.1 to 2500, 0.1 to 2000, 0.1 to 1500, 0.1 to 1400, 0.1 to 1300, 0.1 to 1200, 0.1 to 1100, 0.1 to 1000, 0.1 to 500. 500 to 5000, 500 to 4000, 500 to 3500, 500 to 3000, 500 to 2500, 500 to 2000, 500 to 1500, or 500 to 1000.
[0101] Example B-18. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises a hexane content in ppm in the range of 0 to 250, 0 to 200. 0 to 150, 0 to 100, 0 to 50, 0 to 40, 0 to 35, 0 to 20, 0 to 15, 0 to 10, 0.1 to 250, 0.1 to 200, 0.1 to 150, 0.1 to 100, 0.1 to 50, 0.1 to 40, 0.1 to 35, 0.1 to 20, 0.1 to 15, 0.1 to 10, 5 to 100, 5 to 50, 5 to 40, 5 to 35, 5 to 20, 5 to 15, 5 to 10, 1 to 100, 1 to 50, 1 to 40, 1 to 35, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 10 to 100, 10 to 50, 10 to 40, 10 to 35. 10 to 30, 10 to 20, or 10 to 15.
[0102] Example B-19. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises a nimbin content of less than 0.5 wt%, less than 0.4 wt%, less than 0.3 wt%, less than 0.2 wt%, or less than 0.1 wt%.
[0103] Example B-20. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises a salanin content of less than 1.6 wt%, less than 1.5 wt%. less than 1.4 wt%, less than 1.3 wt%, less than 1.2 wt%, less than 1.1 wt%, less than 1.0 wt%, less than 0.9 wt%, less than 0.8 wt%, less than 0.7 wt%, less than 0.6 wt%, less than 0.5 wt%, less than 0.4 wt%, less than 0.3 wt%, less than 0.2 wt%, or less than 0.1 wt%.
[0104] Example B-21. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises a deacetylnimbin of less than less than 1.0 wt%, less than 0.9 wt%,PT-2365-WO-PCTless than 0.8 wt%, less than 0.7 wt%, less than 0.6 wt%, less than 0.5 wt%, less than 0.4 wt%, less than 0.3 wt%, less than 0.2 wt%, or less than 0.1 wt%.
[0105] Example B-22. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product comprises a deacetylnimbin of less than less than 1.0 wt%, less than 0.9 wt%, less than 0.8 wt%, less than 0.7 wt%, less than 0.6 wt%, less than 0.5 wt%, less than 0.4 wt%. less than 0.3 wt%, less than 0.2 wt%, or less than 0.1 wt%.
[0106] Example B-23. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product is derived from a drying process comprising at least one humidifying step.
[0107] Example B-24. An animal feed additive, complete feed, fish feed, or feed diet comprising the azadirachtin product of any of the preceding examples.
[0108] Example B-25. The animal feed additive, complete feed, fish feed, or feed diet of claim 13, wherein the animal feed additive, complete feed, or feed diet comprises an amount of azadirachtin product effective for use against sea lice in salmonids.
[0109] Example B-26. Use of the azadirachtin product or fish feed of any of the preceding examples for the prevention, mitigation, or elimination of sea lice in salmonids.
[0110] Example B-27. The azadirachtin product of any of the preceding examples, wherein the azadirachtin product is produced by the process of any of examples A-l to A-14.
[0111] Example B-28. A process for producing the azadirachtin product of any of the preceding examples, wherein the process is the process any of examples A-l to A-14.
[0112] Example B-29. A process for producing the azadirachtin product of any of the preceding examples, wherein the process comprises a humidifying step according to any example or part of this disclosure.
Claims
PT-2365-WO-PCTCLAIMSWhat is claimed is:
1. An azadirachtin product, comprising:10 to 35 wt% azadirachtin A,0.1 to 100 ppm hexane,0.1 to 3000 ppm ethyl acetate, and0 to 2 ppm benzene.
2. The azadirachtin product of claim 1, wherein the azadirachtin product comprises azadirachtin B in an amount from 1 to 15 wt%.
3. The azadirachtin product of any of the preceding claims, wherein the azadirachtin product comprises azadirachtin D in an amount from 0.1 to 5 wt%.
4. The azadirachtin product of any of the preceding claims, wherein the azadirachtin product comprises a total content of azadirachtin A, azadirachtin B. and azadirachtin D of from 25 to 45 wt%.
5. The azadirachtin product of any of the preceding claims, wherein the azadirachtin product comprises azadirachtin A in an amount from 25 to 30 wt%.
6. The azadirachtin product of any of the preceding claims, wherein the loss on drying of the azadirachtin product is less than 3%.
7. The azadirachtin product of any of the preceding claims, wherein the azadirachtin product comprises 0.1 to 50 ppm hexane.
8. The azadirachtin product of any of the preceding claims, wherein the azadirachtin product comprises 0.1 to 2500 ppm ethyl acetate.
9. The azadirachtin product of any of the preceding claims, wherein the azadirachtin product contains no detectable benzene.PT-2365-WO-PCT10. The azadirachtin product of any of the preceding claims, wherein the azadirachtin product contains less than 0.5% nimbin.
11. The azadirachtin product of any of the preceding claims, wherein the azadirachtin product contains less than 1.6% salanin.
12. The azadirachtin product of any of the preceding claims, wherein the azadirachtin product comprises a total azadirachtin content (including azadirachtin A, azadirachtin B. azadirachtin D, azadirachtin E, azadirachtin F, azadirachtin G, azadirachtin H, azadirachtin I, azadirachtin K, other azadirachtins, and isomers thereof) of from 50 to 100%.
13. The azadirachtin product of any of the preceding claims, wherein the azadirachtin product is derived from a drying process comprising at least one humidifying step.
14. An animal feed additive, complete feed, fish feed, or feed diet comprising the azadirachtin product of any of the preceding claims.
15. Use of the azadirachtin product or fish feed of any of the preceding claims for the prevention, mitigation, or elimination of sea lice in salmonids.
